首页> 外文期刊>Modern Pathology >Management of flat epithelial atypia on breast core biopsy may be individualized based on correlation with imaging studies
【24h】

Management of flat epithelial atypia on breast core biopsy may be individualized based on correlation with imaging studies

机译:根据与影像学研究的相关性,可以对乳房上皮活检的扁平上皮异型症进行处理

获取原文
           

摘要

Flat epithelial atypia of the breast commonly co-exists with atypical ductal hyperplasia, lobular neoplasia, and indolent forms of invasive carcinomas such as tubular carcinoma. Most patients with pure flat epithelial atypia on core biopsy undergo surgical excision to evaluate for carcinoma in the adjacent breast tissue. Studies to date have reported varying upgrade rates with most recommending follow-up excision. These studies have often lacked detailed radiographic correlation, central review by breast pathologists and information regarding the biology of the carcinomas identified upon excision. In this study, we report the frequency of upgrade to invasive carcinoma or ductal carcinoma in situ in excision specimens following a diagnosis of pure flat epithelial atypia on core biopsy. Radiographic correlation is performed for each case and grade/receptor status of detected carcinomas is reported. Seventy-three (73) core biopsies containing pure flat epithelial atypia were identified from our files, meeting inclusion criteria for the study. In the subsequent excision biopsies, five (7%) cases contained invasive carcinoma or ductal carcinoma in situ and seventeen (23%) contained atypical ductal hyperplasia or lobular neoplasia. All of the ductal carcinoma in situ cases with estrogen receptor results were estrogen receptor positive and intermediate grade. The invasive tumors were small (pT1a) hormone receptor-positive, HER2-negative, low-grade invasive ductal or tubular carcinomas with negative sentinel lymph-node biopsies. No upgrades were identified in the 14 patients who had all of their calcifications removed by the stereotactic core biopsy. Our rate of upgrade to carcinoma, once cases with discordant imaging are excluded, is at the lower end of the range reported in the literature. Given the low upgrade rate and indolent nature of the carcinomas associated with flat epithelial atypia, case management may be individualized based on clinical and radiographic findings. Excision may not be necessary for patients without remaining calcifications following core biopsy.
机译:乳房的扁平上皮非典型性病变通常与非典型性导管增生,小叶赘生物和浸润性癌(例如肾小管癌)并存。大多数接受核心活检的纯扁平上皮非典型性患者接受手术切除,以评估邻近乳腺组织的癌变。迄今为止的研究报告了不同的升级率,其中大多数建议随访切除。这些研究通常缺乏详细的放射学相关性,乳腺病理学家的集中评价以及有关切除后发现的癌的生物学信息。在这项研究中,我们报告了在核心活检诊断为纯扁平上皮异型后,在切除标本中升级为浸润性癌或导管癌的频率。对每种情况进行射线照相相关,并报告检测到的癌的等级/受体状态。从我们的档案中确定了七十三(73)例包含纯平上皮异型性的核心活检,符合本研究的纳入标准。在随后的切除活检中,五(7%)例为浸润性原位癌或导管癌,十七(23%)例为非典型导管增生或小叶赘生物。所有具有雌激素受体结果的导管癌原位病例均为雌激素受体阳性和中等等级。侵袭性肿瘤为小(pT1a)激素受体阳性,HER2阴性,低度侵袭性导管癌或肾小管癌,前哨淋巴结活检阴性。在通过立体定向穿刺活检去除了全部钙化的14例患者中,未发现升级。一旦排除影像学不一致的病例,我们的癌变率就处于文献报道范围的下限。鉴于扁平上皮非典型性癌的低升级率和顽固性,病例治疗可根据临床和影像学检查结果进行个性化处理。对于核心活检后没有残留钙化的患者,可能无需行切除术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号